Skip to main content

Tekmira Acquires License to Novel RNAi Technology for Therapeutic Development

Premium

Tekmira Pharmaceuticals said this week that it has acquired an exclusive, worldwide license to an RNAi technology developed by Halo-Bio RNAi Therapeutics.

The technology, called multivalent RNAi, comprises “single macromolecules capable of mediating RNAi at multiple unique target sites,” Tekmira said. “MV-RNA can target three sites on a single gene or up to three separate genes simultaneously.”

Tekmira said that it aims to combine the molecules with its proprietary lipid nanoparticles to develop therapeutics.

Financial terms of the arrangement were not disclosed.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.